Category: Body Systems
Cortisol is not the villain, the system that produces it is. This is how the HPA axis actually works, what chronic stress does to it over time, and which plants have real evidence for supporting it.
Category: Body Systems | Reading time: ~16 min | Level: Intermediate, Advanced
Cortisol has been made into a sort of "villain" in today's wellness space. Search through virtually any health-related corner of the internet and you will find it blamed for weight gain, brain fog, burnout, and seemingly everything else wrong with modern health. The scientific community has responded predictably, with pleas for "nuance," reminders that cortisol is essential for survival, and gentle mockery of the supplement claims clustered around it.
Both sides are missing the point.
Cortisol is neither good nor bad. It is a glucocorticoid hormone produced by the adrenal cortex in response to a carefully orchestrated chain of hormonal signals, and the system that produces it, the HPA axis, is one of the most consequential and most vulnerable regulatory systems in the human body. Understanding it is not optional for anyone trying to make sense of their energy patterns, sleep quality, mood, immune function, or weight.
This article covers the nervous system from the ground up, the two branches governing stress and recovery, the hormonal cascade connecting your brain to your adrenal glands, what disrupts this system at a physiological level, and what plant medicine actually offers in response. Not through vague adaptogen marketing, but through specific compounds, documented mechanisms, and clinical evidence that is, in several cases, unusually robust for the botanical field.
The nervous system is the body's primary electrochemical communication infrastructure, a network managing heartbeat rhythms, hormonal production, immune messaging, sensory input, and voluntary movement simultaneously. For stress physiology, it divides most usefully into two primary functional branches.
The sympathetic nervous system (SNS) is the activation branch. When it fires, whether due to a physical threat, emotional shock, or even a perceived danger, it triggers a rapid biochemical cascade. Adrenaline and noradrenaline flow from the adrenal medulla. Heart rate climbs. Blood diverts away from digestion and reproductive processes toward skeletal muscle. Bronchioles open. The entire organism reorients toward immediate action. This is the fight-or-flight response: evolutionarily ancient, biochemically precise, and in genuine emergencies, lifesaving.
The parasympathetic nervous system (PNS) operates through different chemistry. Its primary neurotransmitter is acetylcholine, and it travels principally through the vagus nerve, the tenth cranial nerve, running from brainstem through the thoracic cavity to the abdominal region, connecting the brain to the gut, heart, and lungs in a two-way communication pathway. Its function is recovery: reduced heart rate, restored digestive motility, immune maintenance, tissue repair, hormonal rebalancing. Physiologists call this the rest-and-digest state. This is where cellular maintenance takes place. This is where healing occurs.
These two branches were designed to alternate. The SNS handles the demand; the PNS provides for recovery. There should be an automatic, fluid transition between these states in a properly functioning nervous system. A stressor activates the sympathetic cascade; the stressor resolves; cortisol clears; the PNS reasserts dominance.
The key phrase is the stressor resolves.
The human stress response evolved for acute, episodic, physical threats, not for continuous low-grade psychological pressure delivered across months and years. Financial instability, occupational overload, digital saturation, poor sleep, nutritional deficiencies, and relationship tension all activate the SNS without providing the resolution signal that would allow the PNS to recover its ground. The sympathetic system fires. And fires. Cortisol accumulates. The parasympathetic system never fully gets its turn.
This is not merely discomfort. It is physiologically expensive in ways that cascade across nearly every organ system, and understanding exactly how requires understanding the HPA axis.
The HPA axis, the hypothalamic-pituitary-adrenal axis, is the core neurohormonal pathway through which the brain translates perceived stress into a bodily response. Its mechanics are straightforward to describe, but its downstream effects are far-reaching enough that a working understanding of it reframes most conversations about chronic fatigue, disturbed sleep, mood instability, and unexplained weight changes.
When the brain identifies a stressor, real or imagined, physical or psychological, the hypothalamus releases a peptide called corticotropin-releasing hormone (CRH). CRH travels to the anterior pituitary gland, which responds by secreting adrenocorticotropic hormone (ACTH) into the circulatory system. ACTH then reaches the adrenal cortex, the outer layer of the adrenal glands sitting atop each kidney, and triggers cortisol synthesis and release.
Cortisol does not represent a pathological signal. It performs dozens of legitimate regulatory functions: mobilising glucose from stored glycogen to fuel an immediate response, suppressing inflammatory pathways, regulating blood pressure and fluid balance, and, critically, providing the negative feedback signal that tells the hypothalamus to stop producing CRH once the acute threat has passed. In its healthy state, the system is elegantly self-regulating. Cortisol rises, achieves its purpose, and then suppresses its own production. The axis returns to baseline.
What most wellness content fails to account for is cortisol's diurnal rhythm. Cortisol is not simply a stress hormone that spikes when things go wrong. It follows a precise daily curve. During deep sleep, levels are low. In the final hours before waking, as the body transitions into lighter sleep phases, cortisol begins to climb. It peaks approximately 30 to 45 minutes after waking in what researchers call the cortisol awakening response (CAR). In a healthy individual, this morning surge is entirely appropriate: it mobilises energy, activates immune surveillance, and primes cognitive function for the day. Cortisol then drops steadily until the late evening, reaching its lowest point and allowing melatonin to rise, initiating sleep.
This pattern, steep morning rise, gradual diurnal decline, is what a well-functioning HPA axis produces. It is measurable via salivary cortisol testing taken at four to five time points across a single day, and it is one of the most informative functional markers available outside of a clinical laboratory setting.
Dysfunction disrupts this curve, but not always in the same direction. In early or acute chronic stress, the pattern often shows elevation: a blunted or absent morning CAR (the axis is already depleted at waking), elevated afternoon and evening cortisol (the system cannot down-regulate appropriately), and subsequent disruption of sleep onset and architecture. In prolonged, severe dysfunction, termed "adrenal fatigue" in lay literature, and discussed more carefully in endocrinology as HPA axis hypoactivation, the curve flattens: low CAR, low diurnal output, and a generalised inability to mount a proper stress response. This is the physiological substrate of the particular exhaustion that no amount of sleep seems to fix.
This distinction matters enormously for treatment. A person with a high-cortisol, hyperactivated presentation needs different support than someone with a flat, depleted axis, and conflating these two is among the most common errors in both conventional and integrative approaches to chronic fatigue and burnout.
In 1993, neuroscientist Bruce McEwen and Eliot Stellar published a paper in the Archives of Internal Medicine that quietly reshaped how researchers understood chronic stress and disease. Their argument was straightforward: the stress response has a cost, and that cost accumulates.
The concept they articulated was allostatic load, the cumulative physiological wear produced when the adaptive mediators of the stress response (cortisol, adrenaline, inflammatory cytokines) are chronically elevated, chronically suppressed, or chronically dysregulated. The body, in other words, does not simply return to where it started after prolonged stress. It returns changed, with receptors downregulated, inflammatory tone elevated, gut barrier integrity compromised, and hormonal priorities reorganised at a biochemical level.
Because these changes occur across multiple organ systems simultaneously, chronically stressed individuals characteristically present with clusters of apparently unrelated complaints. This is not coincidence. It is the signature of high allostatic load.
In the gut: Chronically elevated cortisol disrupts the expression of tight junction proteins, the molecular gatekeepers maintaining intestinal wall integrity. When these proteins are compromised, bacterial endotoxins and partially digested peptides can cross the intestinal barrier into systemic circulation, triggering immune activation and low-grade inflammation. This mechanism, stress-related intestinal permeability, is documented in peer-reviewed literature, including work by Söderholm and Perdue in the American Journal of Physiology (2006), with subsequent research on the gut-brain axis providing further corroboration.
In the immune system: The effect is paradoxical and chronologically specific. Acute cortisol elevation is powerfully anti-inflammatory, suppressing pro-inflammatory cytokines including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). But chronically elevated cortisol eventually produces glucocorticoid resistance: immune cells downregulate their cortisol receptors, becoming progressively less responsive to its anti-inflammatory signal. The result is persistent low-grade inflammation, the opposite of what cortisol was designed to produce, emerging precisely because the system has been overactivated for too long.
In sleep: Cortisol and melatonin operate in direct competition. Elevated evening cortisol suppresses melatonin production at the pineal gland. This is the mechanism behind a specific sleep disruption pattern familiar to most chronically stressed people: not difficulty falling asleep, but difficulty staying asleep, waking between 2 and 4 AM with an immediately activated mind, when cortisol should be at its nadir but is not.
In metabolic function: Cortisol drives gluconeogenesis and upregulates cortisol receptors in visceral adipose tissue, promoting preferential fat deposition around the abdomen. The phenomenon wellness culture calls "cortisol belly" is a real physiological process, a direct consequence of sustained HPA axis activation, though its treatment is considerably more complex than the supplement industry tends to acknowledge.
In hormonal function: Cortisol, oestrogen, progesterone, and testosterone all share pregnenolone as a common biochemical precursor. When adrenal demand for cortisol is sustained, pregnenolone is diverted toward the cortisol synthesis pathway at the expense of sex hormone production, a process sometimes called the pregnenolone steal. In women, this manifests as blunted progesterone, disrupted cycle regulation, or worsened premenstrual symptoms. In men, it correlates with suppressed testosterone output. It is one of the clearest illustrations of how a chronically activated nervous system does not stay confined to the nervous system, it reorganises the body's biochemical priorities at the most fundamental level.
The term adaptogen has a specific pharmacological meaning that its contemporary wellness usage frequently obscures. It was coined in 1947 by Soviet pharmacologist Nikolai Lazarev to describe substances that increase the body's nonspecific resistance to stress without disrupting normal physiological function. Lazarev's student Israel Brekhman formalised the criteria in the 1960s. An adaptogen must be nontoxic at normal doses, produce a nonspecific resistance to stress across physical, chemical, and biological stressors, and exert a normalising influence on the body regardless of the direction of the pathological shift.
That third criterion is the one that carries the most weight. A true adaptogen does not simply stimulate or sedate. It modulates, moving an underactive system toward activation and an overactivated system toward calm. This bidirectional action is pharmacologically rare, and it is what makes adaptogens relevant specifically to HPA axis dysregulation, where clinical presentations range from high-cortisol hyperarousal to low-cortisol depletion depending on stage and severity of dysfunction.
Ashwagandha (Withania somnifera)
Ashwagandha has, in this assessment, the most clearly established cortisol-modulating evidence base of any botanical currently in widespread commercial use. Its primary active constituents are withanolides, steroidal lactones concentrated in the root, along with alkaloids including somniferine and sitoindosides.
The mechanism through which ashwagandha modulates cortisol output converges on several pathways: inhibition of HPA axis activity at the hypothalamic level (reducing CRH output), enhancement of GABAergic tone through modulation of GABA-A receptor activity (producing the anxiolytic effect), and antioxidant activity within the adrenal cortex, potentially protecting adrenal cells from oxidative damage associated with chronic ACTH stimulation.
The clinical evidence is unusual in its quality for the botanical field. A double-blind, randomised, placebo-controlled trial published in the Indian Journal of Psychological Medicine by Chandrasekhar and colleagues in 2012 enrolled 64 adults with chronic stress histories and administered KSM-66 ashwagandha extract at 300 mg twice daily, or placebo, for 60 days. The ashwagandha group showed a 27.9% reduction in serum cortisol versus 7.9% in the placebo group, statistically significant and clinically meaningful. Stress scores improved 44% versus 5.5% in the placebo arm. A meta-analysis published in Medicine (2021) pooled data from multiple RCTs and confirmed the cortisol-lowering effect across studies, noting that withanolide standardisation between preparations remained a confounding variable in cross-study comparison.
Rhodiola rosea
Rhodiola rosea, from the root of a succulent native to high-altitude Siberia and Scandinavia, has a distinct clinical profile that makes it particularly suited to the acute or early-stage stress presentation, high cortisol, high arousal, fatigue from effort, rather than the depleted, low-cortisol end of the dysfunction arc.
Its primary active compounds are rosavins (phenylpropanoid glycosides) and salidroside (a phenylethanol glycoside). Both demonstrate inhibitory activity at monoamine oxidase A and B, the enzymes responsible for metabolising serotonin, dopamine, and noradrenaline in the synaptic cleft. This is mechanistically related to the action of MAOI antidepressants, but partial and considerably gentler in magnitude.
A randomised controlled trial by Darbinyan and colleagues published in Phytomedicine (2000) demonstrated significant improvement in stress-related fatigue and cognitive performance in young physicians under genuine acute stress load. A 2009 RCT by Olsson and colleagues in the same journal showed meaningful reductions in burnout symptoms over 12 weeks with standardised rhodiola extract, with measurable changes in cortisol output patterns.
The practical clinical distinction matters: ashwagandha tends toward the calming-adaptive end of the spectrum, better suited to high-anxiety or high-cortisol presentations and to evening use. Rhodiola tends toward the activating-adaptive end, better suited to fatigue-dominant or low-cortisol presentations and to morning use. Both address the HPA axis, but at different points in its dysregulation arc and through different primary mechanisms.
The HPA axis is one of two major pharmacological entry points for plant-based nervous system support. The second is the GABAergic system, the network of inhibitory receptors and neurotransmitters that regulates neurological excitability throughout the brain, and which is directly implicated in anxiety, hyperarousal, and sleep onset difficulties.
GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. It binds to GABA-A receptors, ligand-gated chloride ion channels, and reduces the firing threshold of postsynaptic neurons. Enhancing GABAergic signalling reduces anxiety, lowers arousal, and facilitates sleep. Benzodiazepines exploit this mechanism by binding to an allosteric site on the GABA-A receptor complex and amplifying GABA's inhibitory effect. Their clinical problem, as a generation of prescribed patients discovered, is tolerance, physiological dependence, and cognitive side effects. This has driven sustained interest in botanicals that operate through adjacent but gentler mechanisms.
Lemon Balm (Melissa officinalis)
Lemon balm's primary active constituent relevant to nervous system support is rosmarinic acid, a caffeic acid ester present in high concentrations in the plant's aerial parts. Its mechanism is GABA transaminase inhibition: rosmarinic acid slows the enzymatic breakdown of synaptic GABA, raising ambient GABA levels throughout the CNS without directly binding to GABA receptors.
This is a clinically important distinction. Direct GABA-A receptor agonism, as with benzodiazepines, creates receptor desensitisation and the tolerance that underlies dependence. GABA transaminase inhibition produces a gentler, more sustainable increase in GABAergic tone that does not appear to carry the same receptor-level risks at normal botanical doses.
A double-blind, placebo-controlled crossover study by Kennedy and colleagues published in Psychosomatic Medicine (2004) demonstrated significant reductions in anxiety and improved mood with a single dose of standardised lemon balm extract in healthy adults under experimental stress, with effects measurable on validated mood scales within 60 minutes of administration.
Passionflower (Passiflora incarnata)
Passionflower's anxiolytic activity is attributed primarily to chrysin, a flavonoid with documented partial agonist activity at the benzodiazepine binding site on the GABA-A receptor complex. Partial agonism is the mechanistic key: a partial agonist cannot maximally activate the receptor regardless of concentration, creating a pharmacological ceiling that makes receptor downregulation and dependence implausible at therapeutic doses.
A randomised controlled trial by Akhondzadeh and colleagues published in the Journal of Clinical Pharmacy and Therapeutics (2001) compared passionflower extract directly to oxazepam, a standard benzodiazepine, in 36 adults with generalised anxiety disorder. Both treatments produced equivalent reductions in Hamilton Anxiety Rating Scale scores at 28 days. The passionflower group reported significantly less occupational impairment, attributed by the authors to the absence of the sedative side effects measurable in the oxazepam arm.
L-Theanine
L-theanine, the amino acid abundant in Camellia sinensis leaf, produces what sits in a pharmacologically unusual category: alert relaxation without sedation. A 2007 study by Kimura and colleagues in Biological Psychology demonstrated that L-theanine promotes alpha brain wave activity, the oscillatory pattern associated with attentive, meditative calm, without inducing drowsiness. A subsequent study in Nutrients (2019) showed that L-theanine significantly blunted the salivary cortisol response to experimental psychological stress, suggesting a genuine modulatory effect on HPA axis reactivity rather than merely a subjective calming of perceived anxiety.
Sustained HPA-axis activation keeps cortisol elevated, which over time disrupts sleep, blood sugar, immune function, mood and digestion. The cumulative toll is called allostatic load, the wear-and-tear of a stress response that never resets.
The evidence-backed levers are sleep, daylight and circadian regularity, reduced stimulant load, breathwork/vagal activation, and adaptogenic herbs such as ashwagandha. These reduce elevated cortisol toward a healthy baseline rather than crushing it.
The category is loosely used in marketing, but specific adaptogens, notably ashwagandha and rhodiola, have genuine randomised-trial evidence for modulating the stress response. The honest position is selective, not blanket, endorsement.
Adrenal fatigue is not a recognised medical diagnosis; the adrenals rarely run out. What is real is HPA-axis dysregulation, the signalling between brain and adrenals becomes disordered under chronic stress. The distinction matters for choosing the right support.
GABAergic plants can calm acutely within an hour. Adaptogens are cumulative, meaningful cortisol and resilience changes appear over roughly 4 to 8 weeks of consistent use.
Because the problem is almost never a healthy cortisol rhythm, it is a flattened or chronically elevated one from non-stop stress. The goal is not low cortisol, it is a restored rhythm, a proper morning peak and an evening trough. Plants and lifestyle aim to restore that curve, not flatten it.
Different tools for different jobs. For in-the-moment anxiety, a GABAergic plant (lemon balm, passionflower, L-theanine) acts fast. For the underlying overactive stress system, an adaptogen taken daily over weeks does the structural work. Many people use both, fast relief plus slow recalibration.
That pattern usually points to a disrupted cortisol curve (too high at night, too low in the morning). Start with circadian basics, morning daylight, consistent wake time, cutting evening stimulants, then layer an evening-weighted adaptogen like ashwagandha. The "Continue reading" links below go deeper on sleep and ashwagandha.
Honestly, no, and any source claiming otherwise is selling something. Plants modulate the biology, but if the stressor load stays maxed out, you are bailing a boat without plugging the leak. They work best as one part of reducing the actual demand on the system.